MAPT and tauopathy: Inhibitors of GSK3β reduce tauopathy and alleviate neurodegeneration in vivo (Noble et al., 2005), and are therefore considered as therapeutic agents (Engel et al., 2008; Hernandez et al., 2009; Medina et al., 2011) highlighting the role of GSK3β in Tau pathology.